



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 37/00* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2013/056107

(22) International Filing Date:

22 August 2013 (22.08.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/692,853 24 August 2012 (24.08.2012) US
61/774,094 7 March 2013 (07.03.2013) US

(71) Applicant: **GLAXOSMITHKLINE LLC** [US/US]; 5
Crescent Street, Philadelphia, Pennsylvania 19112 (US).

(72) Inventors: **COE, Diane, Mary**; c/o GlaxoSmithKline,
Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY
(GB). **SMITH, Stephen, Allan**; c/o GlaxoSmithKline,
Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY
(GB).

(74) Agents: **COULTER, Kathryn, L.** et al.; c/o GlaxoS-
mithKline, Five Moore Drive, PO Box 13398, Research
Triangle Park, North Carolina 27709 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PYRAZOLOPYRIMIDINE COMPOUNDS



(I)

(57) Abstract: Compounds of formula (I) and salts thereof : wherein R₁ is n-C₁₋₆alkyl or C₁₋₂alkoxyC₁₋₂alkyl-, R₂ is halo, OH or C₁₋₃alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.

